CN111281859B - Chitosan derivative nanoparticles with effect of enhancing antigen presenting cell to present antigen and preparation method thereof - Google Patents
Chitosan derivative nanoparticles with effect of enhancing antigen presenting cell to present antigen and preparation method thereof Download PDFInfo
- Publication number
- CN111281859B CN111281859B CN202010303756.9A CN202010303756A CN111281859B CN 111281859 B CN111281859 B CN 111281859B CN 202010303756 A CN202010303756 A CN 202010303756A CN 111281859 B CN111281859 B CN 111281859B
- Authority
- CN
- China
- Prior art keywords
- chitosan
- molecular weights
- antigen
- derivatives
- different molecular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the technical field of marine organisms, and particularly relates to a method for preparing chitosan nanoparticles with efficient immunologic adjuvant activity for presenting antigen effect. The specific method comprises the following steps: the derivatives with chitosan negative charges and quaternary ammonium salt derivatives with different molecular weights and different substitution sites are prepared into nanoparticles by a polyelectrolyte compounding method, the nanoparticles with certain immunocompetence are screened out, and dendritic cells are treated by experiments to show a good antigen presenting effect. Provides a certain method and theoretical guidance for the research of chitosan as an immunologic adjuvant in recent years.
Description
Technical Field
The invention belongs to the marine biotechnology, and particularly relates to chitosan derivative nanoparticles with the function of enhancing antigen presenting cells to present antigens and a preparation method thereof.
Background
Chitosan is the only natural polysaccharide with positive charge in the nature, and is formed by connecting glucosamine and acetylglucosamine through beta-1, 4 glycosidic bonds. The chitosan has rich sources, is safe and nontoxic, has good biocompatibility and good compatibility with human cells, and has great application potential in the fields of food medicine, agriculture and material science. However, the characteristic that chitosan is insoluble in water limits the application and development of chitosan, and the application of chitosan is more extensive due to derivatization modification to increase the solubility of chitosan. The research of the nanoparticles is one of the research hotspots in recent years, and the utilization of the nanoparticles as a drug carrier is an important research direction of various drugs in medicine at present. The chitosan has good biocompatibility, has no toxic or side effect in organisms and can be degraded by the organisms, and the prepared nanoparticles play a role of a carrier on one hand, so that the development of taking the chitosan as a basic material as a vaccine immunologic adjuvant has certain advantages. The antigen presentation function of the adjuvant is very important in the action process of the vaccine, and the immunogenicity of the vaccine can be enhanced and the immune effect can be improved. Is one of the criteria for testing a material as an immunoadjuvant.
Disclosure of Invention
In view of the above problems, the present invention provides a chitosan derivative nanoparticle with an antigen presenting cell-enhanced antigen presenting effect, and a preparation method and an application thereof.
In order to achieve the purpose, the technical scheme adopted by the experiment is as follows:
a chitosan derivative nanoparticle is prepared by obtaining chitosan derivative nanoparticles with particle size of 162.40nm-332.80nm and potential of 19.5mV-40.60mV by a polyelectrolyte composite method through chitosan negative charge derivatives with different molecular weights and different substitution sites and chitosan positive charge derivatives with different molecular weights; the chitosan positive charge derivatives with different molecular weights and the chitosan negative charge derivatives with different molecular weights and different substitution sites have the mass ratio of 6.25-10: 1-4.
The chitosan negative charge derivatives with different molecular weights and different substitution sites are chitosan carboxymethylation derivatives with different molecular weights and different substitution sites; the chitosan positive charge derivatives with different molecular weights are chitosan quaternary ammonium derivatives with different molecular weights;
the sulfated derivatives of chitosan with different molecular weights and different substitution sites are N.O-site substitution and N-site substitution with the molecular weight range of 3k-1800kDa, and O is substituted carboxymethyl chitosan; preferably N.O-substituted carboxymethyl chitosan with molecular weight of 180-200kDa and N-substituted carboxymethyl chitosan with molecular weight of 180-200K Da.
The quaternary ammonium derivatives of chitosan with different molecular weights are 2, 3-epoxypropyl trimethyl ammonium chloride chitosan derivatives with the molecular weight range of 3k-1800 kDa. Preferred are quaternized derivatives of chitosan with a molecular weight of 180-200 kDa.
A preparation method of chitosan derivative nanoparticles comprises the steps of compounding chitosan negative charge derivatives with different molecular weights and different substitution sites and chitosan positive charge derivatives with different molecular weights into nanoparticles by using polyelectrolyte; wherein, the positive charge and the negative charge derivatives are mixed according to the mass ratio of 6.25-10: 1-4.
The positive and negative charge derivatives are magnetically stirred for 20-40min at room temperature at 500r-700r, and filtered to obtain a nanoparticle solution, which is stored at 4 ℃.
The application of the chitosan derivative nanoparticles is characterized in that: the chitosan derivative nanoparticles are applied to the preparation of vaccine immunologic adjuvants with antigen presentation effects.
An antigen-coated immune vaccine, wherein a vaccine adjuvant is the chitosan derivative nanoparticle, and the mass ratio of the adjuvant to an antigen is 0.5-2: 1, and mixing.
Furthermore, chitosan negative charge derivatives with different molecular weights and different substitution sites are uniformly mixed with the antigen, and then the chitosan positive charge derivatives with different molecular weights are added to prepare the immune vaccine wrapping the antigen through electrostatic adsorption.
The antigen is a substance capable of causing an immune response of the organism, such as a model antigen OVA and an inactivated virus antigen.
The preparation method of antigen-coated immune vaccine is characterized by that after the chitosan negative charge derivatives with different molecular weights and different substitution sites are uniformly mixed with antigen, the chitosan positive charge derivatives with different molecular weights are added, and the antigen-coated immune vaccine can be prepared by means of electrostatic adsorption action.
Furthermore, the chitosan derivative nanoparticles are used for measuring the immunocompetence of dendritic cells. The maximum concentration of the nanoparticles which are not toxic to cells is determined to be 100 mug/mL through cytotoxicity measurement of the uncoated antigen nanoparticles. Through the measurement of the expression quantity of the immune factors and the secretion quantity of the cellular immune factors, the N.O-substituted carboxymethyl chitosan with the molecular weight of 180-200kDa is preferably used as a negative ion chitosan derivative, and the quaternary ammonium salt chitosan is preferably used as a positive ion chitosan derivative, so that the concentration of the carboxymethyl chitosan is 1.5mg/mL and the concentration of the quaternary ammonium salt is 1.0mg/mL under the condition of preparing the nanoparticles, and the nanoparticles have the best immune effect.
The invention has the advantages that:
1. the invention uses the positive and negative ion derivatives of chitosan to prepare the nanoparticles without introducing a cross-linking agent, removes the toxic and side effects of the cross-linking agent, ensures the safety of the nanoparticles in organisms, and has biological safety at proper concentration through the detection of a cytotoxicity test.
2. The nanoparticles prepared by the invention can be used as an immunologic adjuvant, and the immunologic effect verification of the nanoparticles on mouse DCS cells is realized, and the result shows that most of the nanoparticles can promote the expression and secretion of four cytokines of mice, so that the prepared nanoparticles have a certain immunologic effect.
3. The invention uses flow cytometry for detection, and uses MFI (mean fluorescence intensity) to measure the secretion level of the surface protein of the dendritic cells promoted by different nanoparticles, which shows that the prepared nanoparticles have the capability of enhancing the antigen presentation of the dendritic cells. Has good application value in the aspect of preparing the high-efficiency immune adjuvant without side reaction.
Drawings
FIGS. 1A-E are HPLC profiles of the results obtained in example 1 of the present invention for determination of chitosan of different molecular weights; wherein A is 1kDa molecular weight, B is 3kDa molecular weight, C is 5kDa molecular weight, D is 50kDa molecular weight, and E is 200kDa molecular weight.
FIG. 2 is an infrared spectrum of carboxymethylated derivatives of chitosan at different sites obtained in example 3 of the present invention.
Fig. 3 is a graph showing the potential (a) and particle size (B) characteristics of chitosan derivative nanoparticles obtained in example 4 of the present invention.
Fig. 4 is a scanning electron microscope image of the chitosan derivative nanoparticles obtained in example 4 of the present invention.
Fig. 5 is a flow chart of the nanoparticles obtained in example 6 of the present invention for promoting DC cell surface protein secretion.
Detailed Description
The present invention is further described with reference to the drawings attached to the specification, and the scope of the present invention is not limited to the following examples.
The invention takes chitosan as a basis to prepare the nanoparticles and measure the immunocompetence of the nanoparticles, and finally the chitosan derivative nanoparticles with the function of the immunologic adjuvant are obtained.
The specific method comprises the following steps: the chitosan derivative nanoparticles with optimal immunocompetence are obtained through cell experiments by using derivatives with chitosan negative charges with different molecular weights and different substitution sites and quaternary ammonium salt derivatives with different molecular weights to prepare the nanoparticles through a polyelectrolyte composite method, the chitosan derivative nanoparticles prepared from the raw materials under the conditions have no toxic or side effects, and mouse dendritic cell experiments prove that the expression of four immune factor genes of dendritic cells IL-6, TNF-alpha, IL-1 beta and IFN-gamma can be improved, and the secretion of the four types of cytokines can be increased. Four cell surface co-stimulatory molecules, namely MHC-II, CD11c, CD80 and CD86, are detected by a flow cytometer, so that the dendritic cell maturation is promoted, and the dendritic cell antigen presentation effect is enhanced. Provides a certain method and guidance for the research of chitosan derivatives as immunological adjuvants in recent years.
EXAMPLE 1 preparation of chitosans of different molecular weights
Taking 6g of raw material chitosan with the molecular weight of 1820kDa and adding 98mL of H2O, 2mL of acetic acid, stirring at 45 ℃ at the speed of 200r/min for 1h, adding 1g of chitosanase into the mixture, and measuring the molecular weight of the chitosan to be 5138Da after 36 h.
According to the method, raw material chitosan with different molecular weights is degraded by using chitosan enzyme, and the chitosan with different molecular weights and the molecular weight measurement results are shown in the following table 1 and figure 1 only by changing the addition amount of the chitosan enzyme and the reaction time and temperature; in order to ensure that the chitosan obtained by degradation has the same deacetylation degree, the same batch of chitosan is generally used for degradation.
TABLE 1 molecular weight determination of chitosans
Note: wherein the 1820000Da and 210000Da chitosan are obtained by purchase, namely the raw material chitosan.
EXAMPLE 2 preparation of Chitosan Quaternary ammonium salts of different molecular weights
5g of chitosan obtained in the previous example (chitosan with a molecular weight of 5138Da was used in this example) and 10g of 2, 3-epoxypropyltrimethylammonium chloride were used. 70mL of distilled water is added into the mixture, and the mixture is stirred in a water bath at the temperature of 80 ℃ under the condition of the rotating speed of 200r/min, and the reaction time is 24 hours. And dialyzing the obtained reaction solution for 72h by using distilled water in a dialysis bag, and freeze-drying in a freeze dryer at the temperature of minus 80 ℃ to obtain a sample a, namely the chitosan quaternary ammonium salt with the molecular weight of 4740 Da.
In the same method, chitosan quaternary ammonium salts with different molecular weights can be prepared by using chitosan with different molecular weights and 2-epoxypropyltrimethylammonium chloride and 3-epoxypropyltrimethylammonium chloride respectively according to the processes, and the molecular weight measurement results of the obtained chitosan quaternary ammonium salts with different molecular weights are shown in the following table 2.
TABLE 2 results of molecular weight measurement of quaternary ammonium salts
EXAMPLE 3 preparation of carboxymethyl chitosans of different molecular weights and different substitution sites
1) Preparation of N, O-substituted carboxymethyl chitosan with different molecular weights
10g of chitosan obtained in the above examples (chitosan having a molecular weight of 5138Da was used in this example) was added with 100mL of isopropanol and swollen at room temperature for 30 min. 25mL of 10N sodium hydroxide solution was added to the reaction solution in 6 portions with 20min intervals. Adding completely, alkalifying, and stirring for 45 min. And adding 12g of chloroacetic acid into the mixture, adding the chloroacetic acid into the mixture for 5 times at an interval of 5min, and reacting the mixture in a water bath for 3 hours at the temperature of 60 ℃ after the chloroacetic acid is completely added. After completion of the reaction, 9mL of distilled water was added thereto, and the pH was adjusted to 7 with acetic acid. Then dialyzed, frozen and dried to obtain a product b, namely N, O-substituted carboxymethyl chitosan with the molecular weight of 4640 Da.
According to the method, chitosan with different molecular weights is respectively subjected to alkalization by sodium hydroxide and then batch reaction with chloroacetic acid, and then the pH is adjusted to be neutral. The N, O th substituted carboxymethyl chitosan with different molecular weights can be prepared according to the above process, and the measurement results of the molecular weights of the N, O th substituted carboxymethyl chitosan with different molecular weights are shown in the following table 3.
TABLE 3 molecular weight determination of carboxymethyl chitosan at position 3N, O
2) Preparation of O-substituted carboxymethyl chitosan with different molecular weights
Firstly, a mixed solution of water and isopropanol with a volume ratio of 1:4 is prepared, 10g of chitosan with different molecular weights prepared in the previous examples (chitosan with a molecular weight of 5138Da is adopted in the present example) is taken, 13.5g of sodium hydroxide is added into the chitosan, and the mixture is stirred in a water bath and alkalized for reaction for 1 hour at the temperature of 50 ℃. Separately, an isopropyl alcohol solution of chloroacetic acid was prepared, 15g of chloroacetic acid was dissolved in 20ml of isopropyl alcohol solution, and the solution was added dropwise to the reaction solution within 30min, followed by reaction for 4 hours. The reaction was then quenched by the addition of 200mL of 70% ethanol. Dialyzing, freezing and drying to obtain a sample c, namely the O-substituted carboxymethyl chitosan with the molecular weight of 4950 Da.
According to the method, chitosan with different molecular weights is respectively subjected to alkalization by sodium hydroxide and ethanol precipitation after reaction with chloroacetic acid dissolved in isopropanol. The O-substituted carboxymethyl chitosans with different molecular weights can be prepared according to the above process, and the molecular weight measurement results of the O-substituted carboxymethyl chitosans with different molecular weights are shown in table 4 below.
TABLE 4 molecular weight measurement of carboxymethyl chitosan at O-position
3) Preparation of N-substituted carboxymethyl chitosan with different molecular weights
10g of chitosan obtained in the previous examples (chitosan with molecular weight of 5138Da used in this example) was dissolved in 100mL of acetic acid solution with a mass fraction of 1%. To this was added 3.5g of glyoxylic acid. After stirring well, the pH was adjusted to 4.5 using 1N sodium hydroxide. The reaction was stirred at 50 ℃ for 6 h. 0.7g of sodium borohydride is dissolved in 14mL of distilled water to obtain 5% sodium borohydride solution, and the reaction solution is reduced and then reacts for 3 hours. Dialyzing and freeze-drying to obtain a product d. Namely N-substituted carboxymethyl chitosan with the molecular weight of 5030 Da.
According to the method, chitosan with different molecular weights is adopted to react with glyoxylic acid respectively, and then the pH value is adjusted to the optimal reduction condition by sodium hydroxide, and sodium borohydride is used for reduction. The N-substituted carboxymethyl chitosans with different molecular weights can be prepared according to the above process, and the molecular weight measurement results of the obtained N-substituted carboxymethyl chitosans with different molecular weights are shown in the following table 5.
TABLE 5 molecular weight determination of N-carboxymethyl chitosan
EXAMPLE 4 preparation of antigen-coated Chitosan derivative nanoparticles
Reagent: 1.0mg/mL of chitosan quaternary ammonium salt solution a with different molecular weights, 1.5mg/mL of N, O-carboxymethyl chitosan solution, N-carboxymethyl chitosan solution, negative charge derivative solution (for example, O-carboxymethyl chitosan solution) b with different molecular weights and 2.0mg/mL of standard antigen OVA solution m;
taking 5mL of the solution a, putting the solution a in a 25-mL beaker, and placing the beaker in a magnetic stirrer at the rotating speed of 300 r/min. 2mL of the antigen m solution was added dropwise thereto, and after stirring for 10min, 2mL of the negatively charged derivative solution b was further added dropwise thereto. That is, the mass ratio of the positively charged derivative (a) to the chitosan negatively charged derivative (b) having different substitution sites of different molecular weights was 5: 3. Stirring is continued for 30 min. Filtering to obtain nanoparticle solution, storing at 4 deg.C to obtain coated nanoparticles of chitosan derivatives (see Table 6), and determining the particle size range of the nanoparticles as follows: 162.40nm-332.80nm, and the potential range is 19.5mV-40.60 mV.
Meanwhile, the chitosan negative charge derivatives with different molecular weights and different substitution sites and the chitosan positive charge derivatives with different molecular weights obtained in the above examples 1-3 are subjected to different chitosan derivative nanoparticles (see table 6) wrapping the antigen obtained by the above-mentioned recording method, and the molecular weights in the table represent different molecular weights of the quaternary ammonium salt, and the quaternary ammonium salt and the carboxymethyl chitosan have the same molecular weight, and the physical and chemical properties are represented as shown in the table.
TABLE 6 characterization of physicochemical properties of different chitosan derivative nanoparticles encapsulating the antigen
According to the potential and particle size results, in order to ensure the stability of the nanoparticles and better play a better role in carrying and releasing in cells and subsequent animals, the nanoparticles with the particle size of 150-350 nm and the potential of 15-45 mV are obtained. The grain sizes of the NO-CMC-HACC 1800kDa, O-CMC-HACC 1800kDa and N-CMC-HACC 1800kDa samples are not in accordance with the conditions, and the charge amounts of the O-CMC-HACC 200kDa, 50kDa and 3kDa and N-CMC-HACC 3kDa samples are not in accordance with the conditions and are not subjected to subsequent determination. Example 5 Effect of Chitosan derivative nanoparticles on the immunological Activity of DC cells
1) Blank nanoparticles (i.e., chitosan derivative nanoparticles not encapsulating an antigen) and chitosan derivative nanoparticles encapsulating an antigen obtained in the above example were tested for toxicity to DC cells according to CCK-8 method, respectively, as shown in tables 8 and 9.
The mass ratio of the positive charge derivative to the chitosan negative charge derivatives with different molecular weights and different substitution sites is 5: 3.
Table 7 toxicity testing of blank nanoparticles on DC cells
Note: molecular weight means molecular weight of quaternary ammonium salt and carboxymethyl derivative of the same molecular weight
TABLE 8 toxicity test of encapsulated antigen chitosan derivative nanoparticles on DC cells
Note: the molecular weight represents the molecular weight of the quaternary ammonium salt and the carboxymethyl derivative with the same molecular weight, and the antigen is OVA.
The results in tables 7 and 8 show that most of the blank nanoparticles are nontoxic to cells within 100 mu g/mL, most of the coated antigen nanoparticles are nontoxic to cells within 50 mu g/mL, and a few of the coated antigen nanoparticles are nontoxic to cells within 100 mu g/mL.
2) The chitosan derivative nanoparticles prepared in the above example 4 and coated with antigen by chitosan derivatives with different molecular weights and different substitution sites were tested for the influence of fluorescent quantitative PCR on the expression levels of four immune factors IL-6, TNF-alpha, IL-1 beta and IFN-gamma of DC cells, and the experimental results are shown in Table 9.
The fluorescent quantitative PCR: (firstly, an RNA extraction kit is used for extracting total RNA, a NanoDrop 2000 ultramicro ultraviolet \ visible spectrophotometer is used for measuring the RNA content and the RNA quality after the extraction is finished, and then subsequent RNA reversion and quantitative test are carried out, wherein the test PCR test conditions comprise Stage 2, 5s at 95 ℃, 34s at 60 ℃, Stage 3, 15s at 95.)
TABLE 9 influence of antigen-coated chitosan derivative nanoparticles obtained from chitosan derivatives of different molecular weights and different substitution sites on the gene expression level of DC cells
Note: the molecular weight represents the molecular weight of the quaternary ammonium salt and the carboxymethyl derivative with the same molecular weight, and the antigen is OVA. The prepared chitosan derivative nanoparticles coated with the antigen, which are obtained by chitosan derivatives with different molecular weights and different substitution sites, have certain promotion effect on the expression quantity of four cytokines. However, the expression quantities of different nanoparticles are different, and NO-CMC-HACC nanoparticles with the molecular weight of 200k Da and N-CMC-HACC nanoparticles with the molecular weight of 200k Da are the best.
3) The chitosan derivative nanoparticles coated with antigen obtained from the chitosan derivatives with different molecular weights and different substitution sites obtained in example 4 above were assayed for their absorbance at 450nm by ELISA using Elisa kit (abcam mouse kit) at different concentrations, and for the detection of the secretion of cytokines IL-6, TNF- α, IL-1 β, IFN- γ (see tables 10 and 11)
TABLE 10 molecular weight 200kDa NO-CMC-HACC envelope antigen nanoparticle cytokine secretion
| Concentration (μ g/mL) | IL-6(pg/mL) | TNF-α(pg/mL) | IL-1β(pg/mL) | IFN-γ(pg/mL) |
| 0 | 3925.63 | 408.50 | 0.330 | 6.150 |
| 6.25 | 4762.20 | 535.42 | 0.81 | 10.21 |
| 12.5 | 4789.35 | 501.98 | 1.39 | 7.219 |
| 50 | 4867.83 | 1001.17 | 1.82 | 24.85 |
| 100 | 5164.39 | 1736.25 | 2.18 | 22.61 |
TABLE 11 secretion of N-CMC-HACC coated antigen nanoparticle cytokine with molecular weight of 200kDa
| Concentration (μ g/mL) | IL-6(pg/mL) | TNF-α(pg/mL) | IL-1β(pg/mL) | IFN-γ(pg/mL) |
| 0 | 3913.91 | 408.50 | 0.33 | 6.15 |
| 6.25 | 4726.80 | 499.58 | 0.77 | 6.15 |
| 12.5 | 4823.69 | 531.42 | 1.11 | 10.88 |
| 50 | 5080.60 | 507.42 | 1.97 | 22.61 |
| 100 | 5164.39 | 753.58 | 1.64 | 23.70 |
Example 6 Effect of Chitosan derivative nanoparticles on DC cell antigen presentation Effect was analyzed by flow cytometry, the antigen presentation effect of DC cells was measured, and DC cells were cultured in DMEM so that the cell concentration in the culture system was 1X 105 Setting 4 groups of cells/mL in total, then replacing culture media of each group when cells of each group are attached to the wall stably, wherein the culture media replaced by each group are respectively a negative control group by taking DMEM (DMEM), an OVA (OVA assay) is a positive control group, and an experimental group is that N.O-CMC-HACC and N-CMC-HACC nano-particles wrapping antigens (OVA) are respectively added into the DMEM culture media until the final nano-particle concentration in each system is 100 mu g/mL, and culturing for 12 hours; the fluorescent color developing agent labeled antibody is incubated with cells to detect whether the secretion level of the cell marker is influenced by the nanoparticles, so that the influence of the nanoparticles on the antigen presenting cell presenting antigen effect is reflected. MHC-II, CD80, CD86 are important secretions on the cell surface. MHC-II is a complex component of the histocompatibility complex and is the primary complex for presentation of exogenous antigens by DC cells. CD11c, designated complement receptor 4, is an important component of adhesion moleculesAnd belongs to transmembrane glycoprotein. Is highly expressed in dendritic cells, participates in the migration and adhesion process of the dendritic cells and has important functions on antigen recognition and presentation of the dendritic cells. CD80 and CD86 are also cell membrane surface proteins and are important indexes of DC cell maturation and antigen presenting capacity. DC cell surface proteins were assayed using a flow cytometer and complete medium was used as a negative control and OVA as a positive control. The MFI value is calculated. (see Table 12, FIG. 5)
TABLE 12 Effect of nanoparticles on dendritic cell surface costimulatory molecule secretion
The results show that the nanoparticles prepared from the two prepared and screened carboxymethyl chitosans and chitosan quaternary ammonium salts can effectively activate DC cells and enhance the antigen presenting capability of the DC cells.
Claims (5)
1. A preparation method of chitosan derivative nanoparticles with the function of enhancing antigen presentation of antigen presenting cells is characterized in that:
magnetically stirring chitosan negative charge derivatives with different molecular weights and different substitution sites and chitosan positive charge derivatives with different molecular weights at room temperature at 500r/min-700r/min for 20-40min to obtain nanoparticles by polyelectrolyte complex method, filtering, and storing at 4 deg.C;
chitosan derivative nanoparticles with particle size of 162.40nm-332.80nm and potential of 19.5mV-40.60mV are obtained by a polyelectrolyte complex method through chitosan negative charge derivatives with different molecular weights and different substitution sites and chitosan positive charge derivatives with different molecular weights; the chitosan positive charge derivatives with different molecular weights and the chitosan negative charge derivatives with different molecular weights and different substitution sites have the mass ratio of 6.25-10: 1-4;
the chitosan negative charge derivatives with different molecular weights and different substitution sites are chitosan carboxymethylation derivatives with different molecular weights and different substitution sites; the chitosan positive charge derivatives with different molecular weights are chitosan quaternary ammonium derivatives with different molecular weights;
the carboxymethyl derivatives of chitosan with different molecular weights and different substitution sites are N, O-site substitution, N-site substitution and O-site substitution carboxymethyl chitosan with the molecular weight range of 200 kDa;
the quaternary ammonium derivatives of the chitosan with different molecular weights are 2, 3-epoxypropyl trimethyl ammonium chloride chitosan derivatives with the molecular weight range of 200 kDa.
2. Use of chitosan derivative nanoparticles prepared according to claim 1, characterized in that: the chitosan derivative nanoparticles are applied to preparation of vaccine immunologic adjuvants with antigen presentation effects.
3. An antigen-encapsulating immune vaccine, characterized by: the vaccine adjuvant is the chitosan derivative nanoparticles prepared in the claim 1, and the mass ratio of the adjuvant to the antigen is 0.5-2: 1, and mixing.
4. The antigen-encapsulating immune vaccine of claim 3 wherein: the chitosan positive charge derivatives with different molecular weights and different substitution sites are uniformly mixed with the antigen, and then the chitosan negative charge derivatives with different molecular weights are added to prepare the antigen-coated immune vaccine through electrostatic adsorption.
5. A method of preparing the antigen-encapsulating immune vaccine of claim 4, wherein: the chitosan positive charge derivatives with different molecular weights and different substitution sites are uniformly mixed with the antigen, and then the chitosan negative charge derivatives with different molecular weights are added to prepare the antigen-coated immune vaccine through electrostatic adsorption.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019113352177 | 2019-12-23 | ||
| CN201911335217.7A CN110974805A (en) | 2019-12-23 | 2019-12-23 | Chitosan derivative nanoparticles with effect of enhancing antigen presenting cell to present antigen and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111281859A CN111281859A (en) | 2020-06-16 |
| CN111281859B true CN111281859B (en) | 2022-03-22 |
Family
ID=70074162
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911335217.7A Pending CN110974805A (en) | 2019-12-23 | 2019-12-23 | Chitosan derivative nanoparticles with effect of enhancing antigen presenting cell to present antigen and preparation method thereof |
| CN202010303756.9A Active CN111281859B (en) | 2019-12-23 | 2020-04-17 | Chitosan derivative nanoparticles with effect of enhancing antigen presenting cell to present antigen and preparation method thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911335217.7A Pending CN110974805A (en) | 2019-12-23 | 2019-12-23 | Chitosan derivative nanoparticles with effect of enhancing antigen presenting cell to present antigen and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN110974805A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112402621A (en) * | 2020-11-27 | 2021-02-26 | 中国科学院海洋研究所 | Application of sulfate-quaternary ammonium salt chitosan nanoparticles as carrier |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103877566A (en) * | 2013-11-13 | 2014-06-25 | 南京洲邦生物科技有限公司 | Swine broad-spectrum immune enhancement preparation and preparation method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102423304B (en) * | 2011-11-24 | 2013-03-13 | 黑龙江大学 | Preparation method of N-2-hydroxypropyl trimethyl ammonium chloride chitosan/N, O-carboxymethyl chitosan newcastle disease attenuated live vaccine nanoparticle |
| CN102382313B (en) * | 2011-11-24 | 2012-11-28 | 黑龙江大学 | Preparation method of N-2-hydroxypropyl trimethyl ammonium chloride chitosan/ N,O-carboxymethyl chitosan naonparticle |
| CN103212068A (en) * | 2013-05-10 | 2013-07-24 | 黑龙江大学 | Preparation method of chicken infectious bronchitis N-2-hydroxypropyl trimethyl ammonium chloride chitosan/carboxymethyl chitosan nano living vaccine |
| EP3151856B1 (en) * | 2014-06-06 | 2019-08-07 | Merck Patent GmbH | Antigen-loaded chitosan nanoparticles for immunotherapy |
| CN104784685B (en) * | 2015-04-24 | 2018-03-13 | 黑龙江大学 | The preparation method of the hydroxypropyl dimethyl ethyl ammonium chloride chitosan/carboxymethyl chitosan NDV nanoparticles of N 2 |
-
2019
- 2019-12-23 CN CN201911335217.7A patent/CN110974805A/en active Pending
-
2020
- 2020-04-17 CN CN202010303756.9A patent/CN111281859B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103877566A (en) * | 2013-11-13 | 2014-06-25 | 南京洲邦生物科技有限公司 | Swine broad-spectrum immune enhancement preparation and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111281859A (en) | 2020-06-16 |
| CN110974805A (en) | 2020-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Niederhofer et al. | A method for direct preparation of chitosan with low molecular weight from fungi | |
| CN107661504B (en) | Dendritic macromolecule modified gold nanoparticle and preparation method and application thereof | |
| Jin et al. | Antimicrobial activity and cytotoxicity of N-2-HACC and characterization of nanoparticles with N-2-HACC and CMC as a vaccine carrier | |
| EP2370475A1 (en) | Production of a saccharide composition comprising glucans and mannans by alkaline and acid hydrolysis of yeast cells | |
| CN111437385B (en) | Chitosan derivative nanoparticles and preparation method and application thereof | |
| Li et al. | Advances and potential applications of chitosan nanoparticles as a delivery carrier for the mucosal immunity of vaccine | |
| CN111481673B (en) | Preparation method of multi-active-component preparation | |
| CN111281859B (en) | Chitosan derivative nanoparticles with effect of enhancing antigen presenting cell to present antigen and preparation method thereof | |
| PoMohammadur Dounighi et al. | Preparation, characterization and stability investigation of chitosan nanoparticles loaded with the Echis carinatus snake venom as a novel delivery system | |
| Zhang et al. | Effect of ionic strength and mixing ratio on complex coacervation of soy protein isolate/Flammulina velutipes polysaccharide | |
| US20220042058A1 (en) | Exopolysaccharide from Rhodopseudomonas palustris and Method for Preparing and Use Thereof | |
| CN113564069A (en) | Bifidobacterium longum and bifidobacterium longum exopolysaccharide as well as extraction method and application thereof | |
| Kaneko et al. | Evaluation of polymer choice on immunogenicity of chitosan coated PLGA NPs with surface-adsorbed pneumococcal protein antigen PspA4Pro | |
| Quan et al. | Grafting of 18β-glycyrrhetinic acid and sialic acid onto chitosan to produce a new amphipathic chitosan derivative: synthesis, characterization, and cytotoxicity | |
| CN113274490A (en) | Preparation method and application of botryococcus longipediculus polysaccharide disease-resistant inducer | |
| Quan et al. | Ouyang, Q | |
| CN108578386B (en) | Drug for delivering miRNA for inhibiting tumor growth through targeted tumor-associated macrophages and application thereof | |
| US20220249677A1 (en) | Starch-based carrier material with m cell targeting performance and ph responsiveness, and preparation method therefor and use thereof | |
| Il’ina et al. | Nanoparticles based on succinylchitosan with doxorubicin: preparation and properties | |
| CN115028754A (en) | Sulfated hericium erinaceus sporophore beta-glucan, sulfated beta-glucan-chitosan nanoparticle and preparation method and application thereof | |
| CN112156191B (en) | Lysine modified drug carrier and preparation method thereof | |
| CN104324372A (en) | Preparation method of Newcastle disease attenuated vaccine O-2'-hydroxypropyl trimethyl ammonium chloride chitosan nanoparticle sustained-release agent | |
| CN111544586A (en) | Application of nanoparticles with negative charges as immunomodulators | |
| CN114106216A (en) | Hyaluronic acid-astaxanthin nano-composite and preparation method and application thereof | |
| US20170027877A1 (en) | Drug composition and method for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |